• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MBX Biosciences Inc.

    4/22/26 8:05:46 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email
    DEFA14A 1 defa_14a_2026.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material Pursuant to §240.14a-12

     

    MBX BIOSCIENCES, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     

     


     

    img139653606_0.jpgYour Vote Counts! MBX BIOSCIENCES, INC. 2026 Annual MeetingVote by June 3, 2026 11:59 PM ET MBX BIOSCIENCES, INC. 11711 N. MERIDIAN STREET, SUITE 300CARMEL, INDIANA 46032 V93043-P47757 You invested in MBX BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 4, 2026. Get informed before you vote View the Annual Report, Notice and Proxy Statement online at www.proxyvote.com OR you can receive a free paper or emailcopy of the material(s) by requesting prior to May 21, 2026. If you would like to request a copy of the material(s) for thisand/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.comControl # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 4, 2026 8:00 a.m. ET Virtually at: www.virtualshareholdermeeting.com/MBX2026 *Please check the meeting materials for any special requirements for meeting attendance.


    img139653606_1.jpg Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. Election of two Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until such person’s successor is duly elected and qualified, or until their earlier death, resignation or removal: Nominees: 1a. Patrick J. Heron For 1b. Edward T. Mathers For 2. Ratification of the appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V93044-P47757


    Get the next $MBX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    1/28/2026$66.00Overweight
    Barclays
    12/4/2025$18.00Sell
    Goldman
    11/4/2025Buy
    TD Cowen
    10/15/2025$50.00Buy
    Truist
    8/15/2025$36.00Buy
    Jefferies
    8/5/2025$38.00Outperform
    Mizuho
    7/16/2025$38.00Outperform
    Oppenheimer
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    More analyst ratings

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Hoerter Steven L.

    4/A - MBX Biosciences, Inc. (0001776111) (Issuer)

    4/22/26 8:02:02 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Hoerter Steven L.

    4/A - MBX Biosciences, Inc. (0001776111) (Issuer)

    4/22/26 8:01:02 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Smither John W

    3 - MBX Biosciences, Inc. (0001776111) (Issuer)

    3/18/26 4:05:03 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

    CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio of products. For more details and to register for the event, click here. The event will feature Richard DiMarchi, Ph.D. (Distinguished Professor of Chemistry, Indiana University; Scientific Co-Founder, MBX Biosciences, Inc.) a

    4/23/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company's new Chief Business Officer. The inducement award consisted of non-qualified stock options to purchase an aggregate of 130,000 shares of the company's common stock with an exercise price of $32.29 per share, which is equal to the closing price of the company's common stock

    4/3/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

    Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stag

    3/12/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    SEC Filings

    View All

    SEC Form 144 filed by MBX Biosciences Inc.

    144 - MBX Biosciences, Inc. (0001776111) (Subject)

    4/22/26 11:59:16 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by MBX Biosciences Inc.

    DEFA14A - MBX Biosciences, Inc. (0001776111) (Filer)

    4/22/26 8:05:46 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by MBX Biosciences Inc.

    DEF 14A - MBX Biosciences, Inc. (0001776111) (Filer)

    4/22/26 8:04:08 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on MBX Biosciences with a new price target

    Barclays initiated coverage of MBX Biosciences with a rating of Overweight and set a new price target of $66.00

    1/28/26 7:18:07 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on MBX Biosciences with a new price target

    Goldman initiated coverage of MBX Biosciences with a rating of Sell and set a new price target of $18.00

    12/4/25 8:45:53 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on MBX Biosciences

    TD Cowen initiated coverage of MBX Biosciences with a rating of Buy

    11/4/25 7:44:06 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hawryluk P. Kent bought $525,663 worth of shares (18,500 units at $28.41) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    3/16/26 8:02:03 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hawryluk P. Kent bought $272,790 worth of shares (20,000 units at $13.64) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/21/25 5:43:44 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoerter Steven L. bought $264,984 worth of shares (20,000 units at $13.25) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/20/25 4:44:37 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Leadership Updates

    Live Leadership Updates

    View All

    MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

    Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stag

    3/12/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

    CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO). Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries. "Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships

    3/10/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

    CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Laurie Stelzer as an independent director on the Company's Board of Directors and as chairperson of the board's audit committee. Ms. Stelzer brings decades of executive and financial leadership experience with extensive corporate governance, financial oversight, and accounting experience. "I am thrilled to welcome Laurie Stelzer to the Company's Board as an independent director,"

    1/22/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Financials

    Live finance-specific insights

    View All

    MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

    Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney biomarkers All patients completed the 12-week AvailTM trial and 94% entered the OLE Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial Preparation underway to initiate Phase 3 trial in 2026 Company to host conference call at 8:00 am ET today CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on

    9/22/25 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

    CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22. The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast he

    9/19/25 4:18:59 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

    Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

    1/7/25 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/8/24 10:52:39 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/1/24 5:38:56 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MBX Biosciences Inc.

    SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

    9/23/24 6:07:21 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care